# Anterix Inc.: Form 10-Q for the period ended Dec 31, 2020

- Company: [Anterix Inc.](/companies/atex.md) (CIK 1304492)
- Form: 10-Q
- Filed: 2021-02-08
- Accepted by EDGAR: Feb 8, 2021, 16:01 ET
- Period: 2020-12-31
- Accession: 0001304492-21-000003
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1304492/000130449221000003/atex-20201231x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1304492/000130449221000003/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-10-01 to 2020-12-31 | $236.0k | us-gaap:Revenues |
| Revenue | 9 months, 2020-04-01 to 2020-12-31 | $740.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-10-01 to 2020-12-31 | $543.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2020-04-01 to 2020-12-31 | $1.6m | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2020-10-01 to 2020-12-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2020-04-01 to 2020-12-31 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-10-01 to 2020-12-31 | −$12.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-04-01 to 2020-12-31 | −$43.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-10-01 to 2020-12-31 | $155.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-04-01 to 2020-12-31 | $311.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-10-01 to 2020-12-31 | −$12.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-04-01 to 2020-12-31 | −$43.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-10-01 to 2020-12-31 | −$0.69 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2020-04-01 to 2020-12-31 | −$2.51 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2020-04-01 to 2020-12-31 | −$20.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-04-01 to 2020-12-31 | $234.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-12-31 | $108.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-12-31 | $113.0m | us-gaap:AssetsCurrent |
| Total assets | at 2020-12-31 | $241.1m | us-gaap:Assets |
| Current liabilities | at 2020-12-31 | $9.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-12-31 | $21.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-12-31 | $219.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1304492/000130449221000003/atex-20201231x10q.htm

Filed Feb 8, 2021.
Source: SEC EDGAR, the filing index for accession 0001304492-21-000003. Last ingested by Listed: Nov 11, 2026, 00:28 ET. No prices; not investment advice.
